Concepedia

Preparation of Patient Doses of <sup>177</sup> Lu-DOTA-TATE Using Indigenously Produced <sup>177</sup> Lu: The Indian Experience

Tapas Das, Sudipta Chakraborty, Kumar Kallur, Meera Venkatesh, Sharmila Banerjee

Cancer Biotherapy and Radiopharmaceuticals · 2011 · 19 citations · 9 references

DOI

Abstract

The developed method ensures that patient doses of (177)Lu-DOTA-TATE could be prepared with highest possible specific activity depending upon the available specific activity of (177)Lu at the hospital radio-pharmacy.

References

9

Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Radiolabeled Somatostatin Analog [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Dik J. Kwekkeboom, Jaap J.M. Teunissen, Willem H. Bakker et al. · Journal of Clinical Oncology · 2005 · 657 citations · Full text

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Dik J. Kwekkeboom, Willem H. Bakker, Boen L.R. Kam et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 418 citations · Full text

, , +6

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Dik J. Kwekkeboom, Jan Mueller‐Brand, Giovanni Paganelli et al. · PubMed · 2005 · 375 citations

, , +15

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

Wouter A.P. Breeman, Marion de Jong, Theo J. Visser et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 213 citations

, , +9